Rivaroxaban for treatment in venous thrombosis in children

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-000565-47

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary efficacy objective is: To assess the incidence of symptomatic recurrent venous thromboembolism The principal safety objective is:  To assess the incidence of overt major and clinically relevant non-major bleeding.


Critère d'inclusion

  • Venous Thrombosis